Prosecution Insights
Last updated: October 26, 2026

Daesang Corporation

Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials

7 pending office actions • 4 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days

Analysis

Daesang Corporation has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 7 distinct examiners and 6 distinct art units, indicating broad distribution with repeated assignments at both levels.

DIVIESTI, KARLA ISOBEL is the busiest examiner, with 2 pending office actions. That assignment provides a limited basis for examiner-specific planning, but the remaining matters require broader art-unit and application-level analysis.

Counsel should coordinate scientific terminology and prior-art positions while preserving claim-specific reasoning. The repeated art-unit assignments may support targeted review of recurring examination themes without treating the portfolio as a single prosecution file.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

7
Total Pending OAs
3
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
2
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (43%)
4
Medium (57%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (14%)
§103 only3 (43%)
§102 only1 (14%)
Multi-statute (no §101)2 (29%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
DIVIESTI, KARLA ISOBEL 2 3.2% +16.7%
KUBELIK, ANNE R 1 75.8% -1.1%
KIEFER, DALTON EDWARD 1 85.7% +16.7%
DAVIS, RUTH A 1 60.9% +31.0%
NOAKES, SUZANNE MARIE 1 73.4% +18.3%
CONSTANTINE, CHARLES Z 1 59.0% +49.3%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18993136 MUTATED MICROORGANISM OF GENUS CORYNEBACTERIUM WHICH PRODUCES L-GLUTAMIC ACID AND METHOD FOR PRODUCING L-GLUTAMIC ACID USING SAME KIEFER, DALTON EDWARD —

Hard Cases (5)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18269694 ATP-PRT VARIANT WITH REDUCED FEEDBACK INHIBITION BY HISTIDINE, AND HISTIDINE-PRODUCING STRAIN EXPRESSING SAME CONSTANTINE, CHARLES Z 34d
17864715 METHOD OF PRODUCING FLAVOR BY MIXED FERMENTATION OF HETEROLOGOUS MICROORGANISMS DIVIESTI, KARLA ISOBEL 54d
18993134 CORYNEBACTERIUM SP. MUTANT MICROORGANISM PRODUCING L-GLUTAMIC ACID AND METHOD FOR PRODUCING L-GLUTAMIC ACID USING SAME KUBELIK, ANNE R —
18269647 ATP-PRT VARIANT WITH REDUCED FEEDBACK INHIBITION BY HISTIDINE, AND HISTIDINE-PRODUCING STRAIN EXPRESSING SAME NOAKES, SUZANNE MARIE —
18004600 COMPOSITION FOR PRODUCING PROTEIN NOODLES WITH IMPROVED MOUTHFEEL, METHOD FOR PRODUCING PROTEIN NOODLES USING SAME, AND PROTEIN NOODLES PRODUCED BY USING SAME DIVIESTI, KARLA ISOBEL —

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
18269694 ATP-PRT VARIANT WITH REDUCED FEEDBACK INHIBITION BY HISTIDINE, AND HISTIDINE-PRODUCING STRAIN EXPRESSING SAME CONSTANTINE, CHARLES Z 34d
17864715 METHOD OF PRODUCING FLAVOR BY MIXED FERMENTATION OF HETEROLOGOUS MICROORGANISMS DIVIESTI, KARLA ISOBEL 54d
18993136 MUTATED MICROORGANISM OF GENUS CORYNEBACTERIUM WHICH PRODUCES L-GLUTAMIC ACID AND METHOD FOR PRODUCING L-GLUTAMIC ACID USING SAME KIEFER, DALTON EDWARD —
18713941 CORYNEBACTERIUM GLUTAMICUM VARIANT HAVING IMPROVED L-LYSINE PRODUCTION ABILITY AND METHOD FOR PRODUCING L-LYSINE BY USING SAME DAVIS, RUTH A —
18269647 ATP-PRT VARIANT WITH REDUCED FEEDBACK INHIBITION BY HISTIDINE, AND HISTIDINE-PRODUCING STRAIN EXPRESSING SAME NOAKES, SUZANNE MARIE —
18004600 COMPOSITION FOR PRODUCING PROTEIN NOODLES WITH IMPROVED MOUTHFEEL, METHOD FOR PRODUCING PROTEIN NOODLES USING SAME, AND PROTEIN NOODLES PRODUCED BY USING SAME DIVIESTI, KARLA ISOBEL —

Top Art Units

Art UnitApps
1652 3
1792 2
1699 1
1657 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18993134 CORYNEBACTERIUM SP. MUTANT MICROORGANISM PRODUCING L-GLUTAMIC ACID AND METHOD FOR PRODUCING L-GLUTAMIC ACID USING SAME KUBELIK, ANNE R 1652 §101§112 Non-Final OA — Pending Jan 10, 2025
18993136 MUTATED MICROORGANISM OF GENUS CORYNEBACTERIUM WHICH PRODUCES L-GLUTAMIC ACID AND METHOD FOR PRODUCING L-GLUTAMIC ACID USING SAME KIEFER, DALTON EDWARD 1652 §102 Non-Final OA — Pending Jan 10, 2025
18713941 CORYNEBACTERIUM GLUTAMICUM VARIANT HAVING IMPROVED L-LYSINE PRODUCTION ABILITY AND METHOD FOR PRODUCING L-LYSINE BY USING SAME DAVIS, RUTH A 1699 §103 Final Rejection — Pending May 28, 2024
18269647 ATP-PRT VARIANT WITH REDUCED FEEDBACK INHIBITION BY HISTIDINE, AND HISTIDINE-PRODUCING STRAIN EXPRESSING SAME NOAKES, SUZANNE MARIE 1652 §103§112 Non-Final OA — Pending Jul 18, 2023
18269694 ATP-PRT VARIANT WITH REDUCED FEEDBACK INHIBITION BY HISTIDINE, AND HISTIDINE-PRODUCING STRAIN EXPRESSING SAME CONSTANTINE, CHARLES Z 1657 §102§103Other Final Rejection 34d Pending Jun 26, 2023
18004600 COMPOSITION FOR PRODUCING PROTEIN NOODLES WITH IMPROVED MOUTHFEEL, METHOD FOR PRODUCING PROTEIN NOODLES USING SAME, AND PROTEIN NOODLES PRODUCED BY USING SAME DIVIESTI, KARLA ISOBEL 1792 §103 Final Rejection — Pending Jan 06, 2023
17864715 METHOD OF PRODUCING FLAVOR BY MIXED FERMENTATION OF HETEROLOGOUS MICROORGANISMS DIVIESTI, KARLA ISOBEL 1792 §103 Final Rejection 54d Pending Jul 14, 2022

Managing Daesang Corporation's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Daesang Corporation have?

Daesang Corporation has 7 pending office actions as of October 2026, spread across 4 art units and 6 examiners.

Which USPTO examiner handles the most Daesang Corporation applications?

Karla Isobel Diviesti has the most, with 2 of Daesang Corporation's pending office actions.

What technology area are Daesang Corporation's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month